Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate-Reference-Cited by-同舟云学术

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate

Published:2019-01-01 Issue:1 Volume:10 Page:17-29
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Apostolidis Leonidas¹,Nientiedt Cathleen¹,Winkler Eva Caroline¹,Berger Anne Katrin¹,Kratochwil Clemens²,Kaiser Annette³,Becker Anne-Sophie³,Jäger Dirk¹,Hohenfellner Markus⁴,Hüttenbrink Clemens⁵,Pahernik Sascha⁵,Distler Florian A.⁵,Grüllich Carsten¹

Affiliation:

1. Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany

2. Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany

3. Institute of Pathology, Klinikum Nuremberg, Paracelsus Medical University, Nuremberg, Germany

4. Department of Urology, University Hospital Heidelberg, Heidelberg, Germany

5. Department of Urology, Klinikum Nuremberg, Paracelsus Medical University, Nuremberg, Germany

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate;Clinical Genitourinary Cancer;2024-10

2. A case report of sustained remission after radiotherapy combined with ICI in NEPC with primary drug resistance to chemotherapy;Frontiers in Oncology;2024-04-26

3. Lethal disseminated intravascular coagulation induced by primary and metastatic neuroendocrine prostate cancer;IJU Case Reports;2024-02-25

4. Neuroendocrine prostate cancer;Cancer Urology;2023-08-12

5. Treatment outcome after sequential chemotherapy with cisplatin-etoposide, amrubicin and nogitecan in patients with treatment-related pure small-cell neuroendocrine prostate cancer;Japanese Journal of Clinical Oncology;2023-02-24